MYGN

Myriad Genetics Inc. (MYGN) | Rumor.io

Myriad Genetics

MYGN

Attention (50-day avg)0%

Attention rank (50-day avg)#3,344

Bullish sentiment (50-day avg)47%

Price to earnings ratio-1.07

Market capitalization405.6M

Earnings per share-1.18

Dividend yield (TTM)—

Revenue (annual)824.5M

Net income (annual)-365.9M

Social

What share of all stock conversation is about MYGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Mar 17

Myriad Genetics (MYGN) received FDA approval for its MyChoice CDx Test as the companion diagnostic for Zejula (niraparib) in advanced ovarian cancer.
The approval is based on final data from the PRIMA trial, where the MyChoice CDx Test determined homologous recombination deficiency status and was used to stratify advanced ovarian cancer patients.
Insiders are buying up shares of MYGN, indicating potential future price increases.

Generated by AI

Sentiment

Of the messages about MYGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	84.85% +77.71	67.5% -6.58
Bearish	—	100% new	15.15% -77.71	32.5% +6.58

Bullish· Aug 6

$MYGN has shown high relative strength, indicating a strong potential for growth.
The stock has broken out of a bullish pattern, with a massive volume surge and intense momentum on the RSI, suggesting a continuation of the upward trend.
$MYGN has a significant gap to fill above $5.7, which could lead to a strong price increase if it is defended successfully.

Bearish· Feb 7

Myriad Genetics' Q2 EPS and sales results were worse than expected, with the company guiding for lower EPS and revenue in the current quarter and fiscal year.
The company's prenatal business fell short of expectations, and the CEO, Mark Capone, resigned.
JPMorgan lowered its price target for Myriad Genetics to $17 and kept an Underweight rating, suggesting further potential declines.

Generated by AI

Topics

Of the messages about MYGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	20%	67.42%
Technical Analysis	—	—	50%	11.36%
Analysts	—	—	30%	4.55%
Earnings	—	—	0%	12.88%
Controversies	—	—	0%	3.79%
Macro	—	—	0%	0%

Earnings· Aug 21

Myriad Genetics ($MYGN) reported Q4 EPS of $0.38, beating the analyst estimate of $0.33 by $0.05.
Revenue for the quarter came in at $200.9 million, exceeding the consensus estimate of $195.76 million.
The company guided Q1 EPS in-line with estimates, but revenue below expectations, and FY19 EPS above estimates.

Analysts· Aug 14

Myriad Genetics (MYGN) was downgraded to underweight by Barclays PLC.
Analysts at Deutsche Bank, Piper Jaffray Companies, and JP Morgan have cut price targets for MYGN.
Barclays, Deutsche Bank, and Piper Jaffray Companies have downgraded their ratings for MYGN to underweight, neutral, or sell.

Announcements· Nov 1

Myriad Genetics will submit hereditary cancer risk variants to ClinVar in 2023, enhancing data sharing.
Myriad Genetics acquired Gateway Genomics and its SneakPeek Early Gender DNA Test, expanding consumer access to genetic testing.
Myriad Genetics reported third quarter financial results, with a presentation available on the company's website.

Controversies· Jun 13

The US Supreme Court has ruled that human genes cannot be patented, dealing a significant blow to Myriad Genetics, Inc. ($MYGN).
The ruling, which was unanimous, affects Myriad's claim to have the right to exclusively use genetic information associated with breast and ovarian cancer.
The decision has sent Myriad's stock price on a wild ride, with the company's shares initially rising 10% before falling 3% as investors reevaluated the implications of the ruling.

Technical Analysis· Aug 21

TD BUY signal issued for $MYGN at $41.92 with support at $41.67 and resistance at $44.40.
$MYGN is experiencing a stochastic buy signal, with a 7-alarm technical alert.
$MYGN is trading above its 50-day exponential moving average.

Generated by AI

Community

Of the messages about MYGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	20.93%	35.71%
Newcomers	—	0%	79.07%	64.29%

Regulars· May 7

$MYGN's market cap fell to $400M, despite guiding for $800M+ in revenue, with a comparable acquisition of a competitor valued at $600M for $300M in revenue.
The company is trading under 1X revenue, with a potential sell price of $1B+, considering the $40M hit from a major customer dropping Genesight.
Myriad Genetics has announced a RiskScore Study published in JCO Precision Oncology, potentially a positive development for the company.

Newcomers· Feb 24

Newcomers to the stock are optimistic about the healthcare sector, citing it as a strong opportunity in a market where tech is under pressure.
The stock is seeing a significant bid after earnings, with growth story intact and a strong reaction to the news.
Despite recent earnings beat and lawsuit settlement, the stock is experiencing a decline, with a significant drop of -18.9% as shares plummet.

Generated by AI

Myriad Genetics is back in focus after a sharp reset in analyst price targets, with the modelled fair value estimate moving from about US$6.25 to roughly US$3.37, a cut of close to 46%. The shift lines up with more cautious Street commentary that concentrates on execution risk, profitability, and the impact of reduced FY26 guidance on how the stock is valued. As you read on, you will see how to interpret these updates and how to follow the evolving narrative around Myriad Genetics. Stay...

12d agofinance.yahoo.com

1 Unpopular Stock That Deserves Some Love and 2 We Turn Down

Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.

13d agotheglobeandmail.com

Myriad Genetics promotes Vishal Sikri to commercial chief

13d agoInvesting.com

Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026. Vishal has served as the SVP of Product at Myriad for the past year. He has deep understanding of molecular diagnostics and oncology as well as extensive business and commercial leadership experience from his prior roles

14d agoYahoo Finance Singapore

2 Unprofitable Stocks to Research Further and 1 We Find Risky

Detailed price information for Blink Charging Company (BLNK-Q) from The Globe and Mail including charting and trades.

15d agotheglobeandmail.com

Myriad Genetics at Wells Fargo conference: cancer focus amid pressure

19d agoInvesting.com

Also Discussed

Investors talking about MYGN also mention

#	Name	Attention
1	EXAS - Exact Sciences Corporation	——
2	Illumina Inc.ILMN	0%+0
3	Guardant Health Inc.GH	0%-0.11
4	SGEN - Seagen Inc.	——
5	Natera, Inc.NTRA	0%-0.01
6	Labcorp Holdings Inc.LH	0%0
7	Quest Diagnostics IncorporatedDGX	0%0
8	Herbalife Ltd.HLF	0%new
9	Veracyte, Inc.VCYT	0%new
10	Ligand Pharmaceuticals IncorporatedLGND	0%0

Myriad Genetics Inc.

Healthcare
Diagnostics & Research

Myriad Genetics Inc. is a molecular diagnostics and precision medicine company that develops genetic tests to support disease risk assessment, diagnosis, and treatment decisions. The company’s current portfolio spans oncology, women’s health, and pharmacogenomics, with products used for hereditary cancer risk evaluation, tumor profiling, companion diagnostics, reproductive health screening, prenatal testing, and medication-response insights. Its tests are designed for healthcare providers, hospitals, and health systems that use genetic and genomic information to inform patient care across specialties such as cancer, prenatal care, and mental health. Myriad Genetics also offers specialized services that help match patients with targeted therapies and support clinical decision-making through laboratory-based molecular analysis. Headquartered in Salt Lake City, Utah, Myriad Genetics plays an important role in the expanding field of genetic testing, where molecular insights are increasingly integrated into routine medical care.

Website

Location

322 North 2200 West

Salt Lake City, UT, 84116

United States

Social

What share of all stock conversation is about MYGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Mar 17

Myriad Genetics (MYGN) received FDA approval for its MyChoice CDx Test as the companion diagnostic for Zejula (niraparib) in advanced ovarian cancer.
The approval is based on final data from the PRIMA trial, where the MyChoice CDx Test determined homologous recombination deficiency status and was used to stratify advanced ovarian cancer patients.
Insiders are buying up shares of MYGN, indicating potential future price increases.

Generated by AI

Sentiment

Of the messages about MYGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	84.85% +77.71	67.5% -6.58
Bearish	—	100% new	15.15% -77.71	32.5% +6.58

Bullish· Aug 6

$MYGN has shown high relative strength, indicating a strong potential for growth.
The stock has broken out of a bullish pattern, with a massive volume surge and intense momentum on the RSI, suggesting a continuation of the upward trend.
$MYGN has a significant gap to fill above $5.7, which could lead to a strong price increase if it is defended successfully.

Bearish· Feb 7

Myriad Genetics' Q2 EPS and sales results were worse than expected, with the company guiding for lower EPS and revenue in the current quarter and fiscal year.
The company's prenatal business fell short of expectations, and the CEO, Mark Capone, resigned.
JPMorgan lowered its price target for Myriad Genetics to $17 and kept an Underweight rating, suggesting further potential declines.

Generated by AI

Topics

Of the messages about MYGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	20%	67.42%
Technical Analysis	—	—	50%	11.36%
Analysts	—	—	30%	4.55%
Earnings	—	—	0%	12.88%
Controversies	—	—	0%	3.79%
Macro	—	—	0%	0%

Earnings· Aug 21

Myriad Genetics ($MYGN) reported Q4 EPS of $0.38, beating the analyst estimate of $0.33 by $0.05.
Revenue for the quarter came in at $200.9 million, exceeding the consensus estimate of $195.76 million.
The company guided Q1 EPS in-line with estimates, but revenue below expectations, and FY19 EPS above estimates.

Analysts· Aug 14

Myriad Genetics (MYGN) was downgraded to underweight by Barclays PLC.
Analysts at Deutsche Bank, Piper Jaffray Companies, and JP Morgan have cut price targets for MYGN.
Barclays, Deutsche Bank, and Piper Jaffray Companies have downgraded their ratings for MYGN to underweight, neutral, or sell.

Announcements· Nov 1

Myriad Genetics will submit hereditary cancer risk variants to ClinVar in 2023, enhancing data sharing.
Myriad Genetics acquired Gateway Genomics and its SneakPeek Early Gender DNA Test, expanding consumer access to genetic testing.
Myriad Genetics reported third quarter financial results, with a presentation available on the company's website.

Controversies· Jun 13

The US Supreme Court has ruled that human genes cannot be patented, dealing a significant blow to Myriad Genetics, Inc. ($MYGN).
The ruling, which was unanimous, affects Myriad's claim to have the right to exclusively use genetic information associated with breast and ovarian cancer.
The decision has sent Myriad's stock price on a wild ride, with the company's shares initially rising 10% before falling 3% as investors reevaluated the implications of the ruling.

Technical Analysis· Aug 21

TD BUY signal issued for $MYGN at $41.92 with support at $41.67 and resistance at $44.40.
$MYGN is experiencing a stochastic buy signal, with a 7-alarm technical alert.
$MYGN is trading above its 50-day exponential moving average.

Generated by AI

Community

Of the messages about MYGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	20.93%	35.71%
Newcomers	—	0%	79.07%	64.29%

Regulars· May 7

$MYGN's market cap fell to $400M, despite guiding for $800M+ in revenue, with a comparable acquisition of a competitor valued at $600M for $300M in revenue.
The company is trading under 1X revenue, with a potential sell price of $1B+, considering the $40M hit from a major customer dropping Genesight.
Myriad Genetics has announced a RiskScore Study published in JCO Precision Oncology, potentially a positive development for the company.

Newcomers· Feb 24

Newcomers to the stock are optimistic about the healthcare sector, citing it as a strong opportunity in a market where tech is under pressure.
The stock is seeing a significant bid after earnings, with growth story intact and a strong reaction to the news.
Despite recent earnings beat and lawsuit settlement, the stock is experiencing a decline, with a significant drop of -18.9% as shares plummet.

Generated by AI

Myriad Genetics

Social

Mar 17

Bullish· Aug 6

Bearish· Feb 7

Earnings· Aug 21

Analysts· Aug 14

Announcements· Nov 1

Controversies· Jun 13

Technical Analysis· Aug 21

Regulars· May 7

Newcomers· Feb 24

Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset

1 Unpopular Stock That Deserves Some Love and 2 We Turn Down

Myriad Genetics promotes Vishal Sikri to commercial chief

Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

2 Unprofitable Stocks to Research Further and 1 We Find Risky

Myriad Genetics at Wells Fargo conference: cancer focus amid pressure

Also Discussed

Myriad Genetics Inc.

Company Information

Location

Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset

1 Unpopular Stock That Deserves Some Love and 2 We Turn Down

Myriad Genetics promotes Vishal Sikri to commercial chief

Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

2 Unprofitable Stocks to Research Further and 1 We Find Risky

Myriad Genetics at Wells Fargo conference: cancer focus amid pressure

Also Discussed

Social

Mar 17

Bullish· Aug 6

Bearish· Feb 7

Earnings· Aug 21

Analysts· Aug 14

Announcements· Nov 1

Controversies· Jun 13

Technical Analysis· Aug 21

Regulars· May 7

Newcomers· Feb 24